PeptideDB

Werner syndrome RecQ helicase-IN-1 2869954-34-5

Werner syndrome RecQ helicase-IN-1 2869954-34-5

CAS No.: 2869954-34-5

Werner syndrome RecQ helicase-IN-1 (example 42) is a novel DNA helicase (WRN) inhibitor for Werner syndrome RecQ that ha
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Werner syndrome RecQ helicase-IN-1 (example 42) is a novel DNA helicase (WRN) inhibitor for Werner syndrome RecQ that has potential applications in cancer research.

Physicochemical Properties


Molecular Formula C31H31CLF3N9O5
Molecular Weight 702.08335518837
Exact Mass 701.21
CAS # 2869954-34-5
PubChem CID 166140536
Appearance White to light yellow solid powder
LogP 4
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 14
Rotatable Bond Count 7
Heavy Atom Count 49
Complexity 1330
Defined Atom Stereocenter Count 0
SMILES

C12=NC(C3=CCOCC3)=NN1C(=O)C(N1CCN(C(C3C(O)=C(C)N=CN=3)=O)CC1)=C(CC)N2CC(NC1=CC=C(C(F)(F)F)C=C1Cl)=O

InChi Key XKYVECRUZPCRQR-UHFFFAOYSA-N
InChi Code

InChI=1S/C31H31ClF3N9O5/c1-3-22-25(41-8-10-42(11-9-41)28(47)24-26(46)17(2)36-16-37-24)29(48)44-30(39-27(40-44)18-6-12-49-13-7-18)43(22)15-23(45)38-21-5-4-19(14-20(21)32)31(33,34)35/h4-6,14,16,46H,3,7-13,15H2,1-2H3,(H,38,45)
Chemical Name

N-[2-chloro-4-(trifluoromethyl)phenyl]-2-[2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-[4-(5-hydroxy-6-methylpyrimidine-4-carbonyl)piperazin-1-yl]-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidin-4-yl]acetamide
Synonyms

Werner syndrome RecQ helicase-IN-1
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro For WRN ATPase, Werner syndrome RecQ helicase-IN-1 (example 42) has an IC50 value of 100 nM, and for SW48 and DLD1 WRN-KO cell lines, it has GI50 values of 50 nM and >10 μM, respectively[1].
References

[1]. Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn). WO2022249060.


Solubility Data


Solubility (In Vitro) DMSO : ~100 mg/mL (~142.4 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.4243 mL 7.1217 mL 14.2434 mL
5 mM 0.2849 mL 1.4243 mL 2.8487 mL
10 mM 0.1424 mL 0.7122 mL 1.4243 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.